NCT01639456 arm group ad777684fde71cc710c2e243d7379946 [clinicaltrials_resource:NCT01639456/arm-group/ad777684fde71cc710c2e243d7379946]
CliniMACS® CD3 and CD19 Reagent System [clinicaltrials_resource:1225ac738fd69e3c6eb8224ca4371fba]CD3-CD56+ natural killer cells [clinicaltrials_resource:29bed5f10794606a1d3d7baca84b8b52]Fludarabine [clinicaltrials_resource:2d4b0d594d84f938846d0c9632c6d8cc]Cyclophosphamide [clinicaltrials_resource:3349e68263b1eb298b4bb48c19ba26a7]Aldesleukin [clinicaltrials_resource:43dd63701c32196217c97ee82e3ffeba]CliniMACS® CD56 Reagent System [clinicaltrials_resource:81b4ea2f7afb150b844dd35dfac3bffb]clinicaltrials:NCT01639456
arm group [clinicaltrials_vocabulary:arm-group]
NCT01639456 arm group ad777684fde71cc710c2e243d7379946 [clinicaltrials_resource:NCT01639456/arm-group/ad777684fde71cc710c2e243d7379946]
Bio2RDF identifier
NCT01639456/arm-group/ad777684fde71cc710c2e243d7379946
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 777684fde71cc710c2e243d7379946
description [clinicaltrials_vocabulary:description]
Patients receive the apheresis ...... , Fludarabine and Aldesleukin.
identifier
clinicaltrials_resource:NCT01639456/arm-group/ad777684fde71cc710c2e243d7379946
title
NCT01639456 arm group ad777684fde71cc710c2e243d7379946
@en
type
label
NCT01639456 arm group ad777684 ...... 77684fde71cc710c2e243d7379946]
@en